See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that contributes to inflammation and the symptoms of these conditions [1].

According to the Cosentyx prescribing information, live vaccines should be avoided in patients receiving Cosentyx [2]. This is because Cosentyx can affect the immune system and potentially reduce the effectiveness of live vaccines [2]. Additionally, there is a risk that the live vaccine strain could cause infection in patients taking Cosentyx [2].

It is important to note that this recommendation is not unique to Cosentyx, as other monoclonal antibody medications also have similar warnings regarding live vaccine administration [3].

In summary, Cosentyx can interfere with live vaccine administration due to its potential effects on the immune system and the risk of infection from live vaccine strains.

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Feb 14]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Cosentyx (secukinumab) injection, for subcutaneous use [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022.
3. Live vaccines and immunosuppressive drugs [Internet]. Centers for Disease Control and Prevention. [cited 2023 Feb 14]. Available from: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocomp.html>.
4. Secukinumab [Internet]. DrugPatentWatch.com. [cited 2023 Feb 14]. Available from: <https://www.drugpatentwatch.com/drugs/secukinumab>.